Beigene

This early-stage study tested a new drug called BGB-A3055, both alone and combined with another cancer drug (tislelizumab), in people with advanced solid tumors that had spread. The main goals were to find a safe dose and see if the treatment showed early signs of fighting the ca…

This early-stage study aimed to find a safe dose of a new drug called BGB-24714 for people with advanced solid tumors that have spread or cannot be removed by surgery. Researchers tested the drug alone and combined with chemotherapy or radiation to see how well patients tolerated…

This study aimed to compare a new immunotherapy drug, tislelizumab, against standard chemotherapy for people with Hodgkin lymphoma that had returned or stopped responding to previous treatments. The goal was to see if the new drug could help patients live longer without their can…

This is an early-stage study to test the safety and find the right dose of a new drug called BGB-B3227 for people with advanced or metastatic solid tumors. The drug will be tested both by itself and in combination with another cancer drug, tislelizumab. The main goals are to see …

This early-stage study tested a new oral drug called BGB-30813, both alone and combined with the immunotherapy drug tislelizumab, in people with advanced cancers that had spread. The main goals were to find safe doses and check for early signs that the treatments might help shrin…